FDA granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection
Read more: FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer